Notice for International Patients & Caregivers

English summary does not mean the trial enrolls international patients. Multiple myeloma interventional clinical trials in China typically require valid Chinese resident identity/national healthcare insurance and strict adherence to China's Human Genetic Resources Administration regulations.

Provincial Landscape

Snapshot: 2026-09-04

Liaoning Multiple Myeloma Active Trials & Centers

As of 2026-09-04, there are 35 active clinical trials for multiple myeloma hosted across 8 tertiary medical centers in Liaoning (including Shengjing Hospital of China Medical University, The First Hospital of China Medical University, Zhongshan Hospital Affiliated to Dalian University, etc.).

Active Trials

Hospitals

Therapies

CAR-T Cell Therapy / Bispecific & Multispecific Antibodies / Monoclonal Antibodies / Oral Small-Molecule Agents

Participating Medical Centers (8)

Shengjing Hospital of China Medical UniversityThe First Hospital of China Medical UniversityZhongshan Hospital Affiliated to Dalian UniversityThe Second Hospital of Dalian Medical UniversityShengjing Hospital of China Medical University (The Second Affiliated Hospital of China Medical University)Liaoning Cancer HospitalMa'anshan People's Hospital中国医科大学附属盛京

Active Studies in Liaoning (35)

Population synthesized by CMDN

Showing 0 published English records of 35 registry trials.

All 35 local registry studies currently have Chinese-only filings. Verified English summaries will be published upon regulatory audit.

Back to National Landscape Filter Local Trials in the Trial Hub